Nvidia(US:NVDA) Benzinga·2026-01-07 13:45Core Viewpoint - Salarius Pharmaceuticals, Inc. will change its corporate name to Decoy Therapeutics Inc. and its shares will trade under the ticker symbol DCOY starting January 8, 2026, reflecting a strategic focus on developing peptide-conjugate therapeutics [2][3]. Company Overview - Decoy Therapeutics is a preclinical-stage biotechnology company utilizing machine learning and AI tools to design and manufacture peptide conjugate drug candidates targeting unmet medical needs, particularly in respiratory viruses and gastrointestinal cancers [7]. Strategic Focus and Plans - The company aims to advance its lead antiviral program into clinical trials while expanding its pipeline and partnership opportunities, with a capital-efficient plan for 2026 [2][4]. - The 2026 priorities include executing a focused approach to achieve multiple value-creating milestones and retaining upside through partnerships and non-dilutive funding [6]. Technology and Innovation - Decoy's proprietary peptide-conjugate platform is designed to selectively intercept and neutralize high-value biological targets, with initial programs addressing pan-coronavirus activity and other viral threats [4]. - The company is leveraging an AI-enabled discovery engine to accelerate candidate selection and is pursuing strategic collaborations with big pharma, technology leaders, and academic institutions [10]. Funding and Partnerships - Decoy has attracted financing from institutional investors and significant capital from various sources, including the Massachusetts Life Sciences Seed Fund and the Google AI startup program [7]. - The lead antiviral program has garnered interest from the Biomedical Advanced Research and Development Authority (BARDA) and global health organizations, positioning the company for additional funding and collaborations [4].